Atrium Therapeutics, Inc. Common Stock • RNA

Capital at risk.

About Atrium Therapeutics, Inc. Common Stock
Ticker
info
RNA
Trading on
info
NASDAQ
ISIN
info
US05370A1088
Industry
info
Biotechnology
Sector
info
Healthcare
CEO
info
Kathleen P. Gallagher
Headquarters
info
10578 Science Center Drive, San Diego, CA, United States, 92121
Employees
info
511
Website
info
https://atriumtherapeutics.com
Atrium Therapeutics, Inc., a biopharmaceutical company, focuses on delivering ribonucleic acid (RNA) therapeutics to the heart to transform the care for people living with cardiomyopathies. The company's development stage product candidates include ATR 1072, a siRNA-based therapy targeting PRKAG2 for the treatment of PRKAG2 syndrome; and ATR 1086, a siRNA-based therapy targeting PLN for the treatment of PLN cardiomyopathy. It also focuses on pipeline to treat a range of genetic and cardiac diseases. The company was incorporated in 2025 and is headquartered in San Diego, California.
Metrics
BasicAdvanced
Market cap
info
$209M
P/E ratio
info
-
EPS
info
-$4.48
Dividend Yield
info
0.00%
Beta
info
0.93
Forward P/E ratio
info
0
EBIDTA
info
$-49.3M
Ex dividend date
info
-
Price & volume
Market cap
info
$209M
Average daily volume
info
0.8M
90-day return
info
-
30-day return
info
-
7-day return
info
-
Dividends
Dividend per share
info
$0.00
Dividend yield
info
0.00%
Forward dividend per share
info
$0.00
Forward dividend yield
info
0.00%
Payout ratio
info
0.00%
Valuation
P/E ratio
info
0
Forward P/E
info
0
PEG ratio
info
0
Trailing P/E
info
0
Price to sales
info
11.23
Price to book
info
1.01
Earnings
EPS
info
-$4.48
EPS estimate (current quarter)
info
-$1.26
EPS estimate (next quarter)
info
-$1.29
EBITDA
info
$-49.3M
Revenues (TTM)
info
$18.6M
Revenues per share (TTM)
info
$1.20
Technicals
Beta
info
0.93
52-week High
info
$73.06
52-week Low
info
$11.95
50-day moving average
info
$14.03
200-day moving average
info
$14.03
Short ratio
info
0.05
Short %
info
6.62%
Management effectiveness
ROE (TTM)
info
-43.98%
ROA (TTM)
info
-399.25%
Profit margin
info
-265.88%
Gross profit margin
info
$-25.6M
Operating margin
info
-3,387.89%
Growth
Quarterly earnings growth (YoY)
info
0.00%
Quarterly revenue growth (YoY)
info
-71.10%
Share stats
Outstanding Shares
info
15.5M
Float
info
15M
Insiders %
info
2.79%
Institutions %
info
5.45%
Analyst Insights & forecasts
info

100% Buy

0% Hold

0% Sell

Based on information from 15 analysts.

Average price target

info
$25.00
Earnings per share (EPS) forecast
windowbar_chart_4_bars
Actual
info
Expected
info
Surprise
info
-$0.90
-$0.88
-2.24%
Q1 • 25Missed
-$1.21
-$0.96
-26.54%
Q2 • 25Missed
-$1.27
-$1.14
-11.40%
Q3 • 25Missed
-$1.59
-$1.24
-28.23%
Q4 • 25Current
QuarterlyAnnual
Financial Performance
windowbar_chart_4_bars
Income StatementBalance SheetCash Flow
windowbar_chart_4_bars
Revenue
info
Net income
info
Profit margin
info
$12.5M
$-174M
-1,398.33%
Q3 • 25
$0.9M
$-48.1M
-5,595.93%
Q4 • 25
-93.11%
-72.44%
300.19%
QoQ growth
QuarterlyAnnual
Totals assets
info
Total liabilities
info
Debt to assets
info
$278M
$64.7M
23.31%
Q3 • 25
$278M
$71.1M
25.53%
Q4 • 25
0.29%
9.85%
9.54%
QoQ growth
QuarterlyAnnual
Operating
info
Investing
info
Financing
info
Free cash flow
info
$-156M
$-588M
$850M
$-160M
Q3 • 25
$-19.3M
-
$20.1M
$-20.1M
Q4 • 25
-87.67%
-
-97.63%
-87.42%
QoQ growth
QuarterlyAnnual

Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Past performance is no guarantee of future results. Your return may be affected by currency fluctuations and applicable fees and charges. The value of your investment may go up as well as down. When investing, your capital at risk.

Build your future fund today!

Automate your wealth-building journey and turn investing into a habit that your future self will be grateful for!

Capital at risk.

FAQs

How much is a Atrium Therapeutics, Inc. Common Stock share?
Collapse

Atrium Therapeutics, Inc. Common Stock shares are currently traded for undefined per share.

How many shares does Atrium Therapeutics, Inc. Common Stock have?
Collapse

Atrium Therapeutics, Inc. Common Stock currently has 15.5M shares.

Does Atrium Therapeutics, Inc. Common Stock pay dividends?
Collapse

No, Atrium Therapeutics, Inc. Common Stock doesn't pay dividends.

What is Atrium Therapeutics, Inc. Common Stock 52 week high?
Collapse

Atrium Therapeutics, Inc. Common Stock 52 week high is $73.06.

What is Atrium Therapeutics, Inc. Common Stock 52 week low?
Collapse

Atrium Therapeutics, Inc. Common Stock 52 week low is $11.95.

What is the 200-day moving average of Atrium Therapeutics, Inc. Common Stock?
Collapse

Atrium Therapeutics, Inc. Common Stock 200-day moving average is $14.03.

Who is Atrium Therapeutics, Inc. Common Stock CEO?
Collapse

The CEO of Atrium Therapeutics, Inc. Common Stock is Kathleen P. Gallagher.

How many employees Atrium Therapeutics, Inc. Common Stock has?
Collapse

Atrium Therapeutics, Inc. Common Stock has 511 employees.

What is the market cap of Atrium Therapeutics, Inc. Common Stock?
Collapse

The market cap of Atrium Therapeutics, Inc. Common Stock is $209M.

What is the P/E of Atrium Therapeutics, Inc. Common Stock?
Collapse

The current P/E of Atrium Therapeutics, Inc. Common Stock is null.

What is the EPS of Atrium Therapeutics, Inc. Common Stock?
Collapse

The EPS of Atrium Therapeutics, Inc. Common Stock is -$4.48.

What is the PEG Ratio of Atrium Therapeutics, Inc. Common Stock?
Collapse

The PEG Ratio of Atrium Therapeutics, Inc. Common Stock is 0.

What do analysts say about Atrium Therapeutics, Inc. Common Stock?
Collapse

According to the analysts Atrium Therapeutics, Inc. Common Stock is considered a buy.